9 research outputs found
Clopidogrel treatment may associate with worsening of endothelial function and development of new digital ulcers in patients with systemic sclerosis: results from an open label, proof of concept study
HDL particle functionality as a primary pharmacological target for HDL-based therapies
Despite all existing pharmaceuticals aiming at effectively reducing LDL
cholesterol, the steadily increasing prevalence of coronary heart
disease (CHD) worldwide shifted focus on HDL as an alternative
therapeutic target for the treatment of CHD. Indeed, based on the
results from epidemiological studies, high HDL cholesterol (HDL-C)
levels have been traditionally associated to atheroprotection.
Therefore, current drug design considers plasma HDL-C levels as a
primary pharmacological target for combating CHD. However, this approach
does not take into consideration the fact that HDL is a rather
heterogeneous mixture of lipoprotein particles with distinct
apolipoprotein and lipid composition that dictate their atheroprotective
or proatherogenic function. This may explain why simply raising HDL-C
levels by pharmacological means has yet to yield the expected
atheroprotection in recent clinical trials. In this review we argue that
HDL particle functionality rather than HDL-C levels should be the
primary target in the rational design of new HDL-based pharmaceuticals
aiming at successfully treating CHD. (C) 2013 Elsevier Inc. All rights
reserved
Digital state-feedback control of an interleaved DC–DC boost converter with bifurcation analysis
Peer-to-peer energy trading for improving economic and resilient operation of microgrids
Aldosterone receptor blockade inhibits degenerative processes in the early stage of calcific aortic stenosis
Digital state-feedback control of an interleaved DC–DC boost converter with bifurcation analysis
Identification of Early Pathological Events in Calcific Aortic Valve Disease by Molecular Imaging
Assessing the cardiology community position on transradial intervention and the use of bivalirudin in patients with acute coronary syndrome undergoing invasive management: results of an EAPCI survey.
AIMS: Our aim was to report on a survey initiated by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) collecting the opinion of the cardiology community on the invasive management of acute coronary syndrome (ACS), before and after the MATRIX trial presentation at the American College of Cardiology (ACC) 2015 Scientific Sessions. METHODS AND RESULTS: A web-based survey was distributed to all individuals registered on the EuroIntervention mailing list (n=15,200). A total of 572 and 763 physicians responded to the pre- and post-ACC survey, respectively. The radial approach emerged as the preferable access site for ACS patients undergoing invasive management with roughly every other responder interpreting the evidence for mortality benefit as definitive and calling for a guidelines upgrade to class I. The most frequently preferred anticoagulant in ACS patients remains unfractionated heparin (UFH), due to higher costs and greater perceived thrombotic risks associated with bivalirudin. However, more than a quarter of participants declared the use of bivalirudin would increase after MATRIX. CONCLUSIONS: The MATRIX trial reinforced the evidence for a causal association between bleeding and mortality and triggered consensus on the superiority of the radial versus femoral approach. The belief that bivalirudin mitigates bleeding risk is common, but UFH still remains the preferred anticoagulant based on lower costs and thrombotic risks